ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Biopharma and CROs to benefit from simplified access to global research sites
Dr Sai Satish, Sr. Consultant Interventional Cardiologist performs India’s first 3 successful G4-Transcatheter Edge to Edge (G4–TEER) mitral valve repairs
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Subscribe To Our Newsletter & Stay Updated